Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial by Raemaekers, J. M. M. et al.
Omitting Radiotherapy in Early Positron Emission
Tomography–Negative Stage I/II Hodgkin Lymphoma Is
Associated With an Increased Risk of Early Relapse: Clinical
Results of the Preplanned Interim Analysis of the
Randomized EORTC/LYSA/FIL H10 Trial
John M.M. Raemaekers, Marc P.E. Andre´, Massimo Federico, Theodore Girinsky, Reman Oumedaly,
Ercole Brusamolino,† Pauline Brice, Christophe Ferme´, Richard van der Maazen, Manuel Gotti,
Reda Bouabdallah, Catherine J. Sebban, Yolande Lievens, Allessandro Re, Aspasia Stamatoullas,
Frank Morschhauser, Pieternella J. Lugtenburg, Elisabetta Abruzzese, Pierre Olivier, Rene-Olivier Casasnovas,
Gustaaf van Imhoff, Tiana Raveloarivahy, Monica Bellei, Thierry van der Borght, Stephane Bardet,
Annibale Versari, Martin Hutchings, Michel Meignan, and Catherine Fortpied
Processed as a Rapid Communication manuscript. See accompanying editorial on page 1180
Author affiliations appear at the end of
this article.
Published online ahead of print at
www.jco.org on March 17, 2014.
Supported by Fonds Cancer (Belgium);
Dutch Cancer Society (the Nether-
lands); Institut National du Cancer,
Fondation Contre le Cancer, Assistance
Publique Hopitaux Paris, and Societe
Franc¸aise de Medecine Nucleaire et
Imagerie Moleculaire (France); Associ-
azone Angela Serra (Italy); and Chugai
Pharmaceutical (Japan).
M.M. and C.F. contributed equally to
this work.
†Deceased.
Presented (preliminary results) at the
51st Annual Meeting of the American
Society of Hematology (ASH), New
Orleans, LA, December 5-8, 2009;
Eighth International Symposium on
Hodgkin Lymphoma, Cologne,
Germany, October 23-26, 2010; and
54th ASH Annual Meeting, Atlanta, GA,
December 8-11, 2012.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Clinical trial information: NCT00433433.
Corresponding author: John M.M.
Raemaekers, MD, PhD, Department of
Hematology, Radboud University Medi-
cal Center, PO Box 9101, 6500HB
Nijmegen, the Netherlands; e-mail:
john.raemaekers@radboudumc.nl.
© 2014 by American Society of Clinical
Oncology
0732-183X/14/3212w-1188w/$20.00
DOI: 10.1200/JCO.2013.51.9298
A B S T R A C T
Purpose
Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin
lymphoma (HL). We hypothesized that an early positron emission tomography (PET) scan
could be used to adapt treatment. Therefore, we started the randomized EORTC/LYSA/FIL
Intergroup H10 trial evaluating whether involved-node radiotherapy (IN-RT) could be omitted
without compromising progression-free survival in patients attaining a negative early PET scan
after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared
with standard combined-modality treatment.
Patients and Methods
Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible. Here we report
the clinical outcome of the preplanned interim futility analysis scheduled to occur after
documentation of 34 events in the early PET–negative group. Because testing for futility in this
noninferiority trial corresponds to testing the hypothesis of no difference, a one-sided
superiority test was conducted.
Results
The analysis included 1,137 patients. In the favorable subgroup, 85.8% had a negative early PET
scan (standard arm, one event v experimental arm, nine events). In the unfavorable subgroup,
74.8% had a negative early PET scan (standard arm, seven events v experimental arm, 16 events).
The independent data monitoring committee concluded it was unlikely that we would show
noninferiority in the final results for the experimental arm and advised stopping random
assignment for early PET–negative patients.
Conclusion
On the basis of this analysis, combined-modality treatment resulted in fewer early progressions in
clinical stage I/II HL, although early outcome was excellent in both arms. The final analysis will
reveal whether this finding is maintained over time.
J Clin Oncol 32:1188-1194. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Standard treatment for patients with clinical stage
I/II Hodgkin lymphoma (HL) consists of the com-
bination of chemotherapy (mostly ABVD [doxoru-
bicin, bleomycin, vinblastine, and dacarbazine])
followed by radiotherapy (RT).1,2 Despite the reduc-
tion of RT fields from extended field to involved
node (IN),3 there has been a continuing attempt to
omit RT to reduce late complications.4 Prognostic
factors have yet to reproducibly identify those who
can be treated with chemotherapy alone. Patients
have a significantly higher risk of recurrence after
chemotherapy alone than after combined-modality
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treatment.5-7 Because of adequate but intensive salvage treatment,
overall survival does not differ significantly. The right balance between
initial cure through combined-modality treatment—accepting a
higher risk of late complications—and a higher recurrence rate after
omitting RT in subsets of patients who will subsequently need
intensive salvage treatment (often including autologous stem-
cell transplantation) is a matter of an unsettled debate.8-12 Early
[18F]fluorodeoxyglucose–positron emission tomography (PET) scan-
ning after two cycles of chemotherapy provides prognostic informa-
tion on final outcome; patients who attain a negative early PET scan
after two cycles of ABVD (or similar) chemotherapy have better
progression-free survival (PFS) than those with a positive early PET
scan, when the initially planned treatment is completed.13-15 Patients
with a negative early PET scan might be treated less intensively in view
of the excellent prognosis. We hypothesized that patients with stage
I/II disease who achieve a negative early PET scan could be spared
additional RT. In contrast, those with a positive early PET scan
might benefit from early treatment intensification16 from ABVD to
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone) escalated.
We initiated a randomized controlled phase III intergroup trial
to evaluate primarily the efficacy of chemotherapy alone versus
combined-modality treatment in patients with a negative early PET
scan after two cycles of ABVD. Second, we evaluated the efficacy of
intensification of chemotherapy in patients with a positive early PET scan
after two cycles of ABVD.17 A preplanned interim analysis was conducted
afterapredefinednumberofeventshadoccurredduringthecourseof the
trial to detect possible worse early outcome of the experimental arm. Our
report describes the results of this preplanned interim futility analysis
performed among patients with a negative early PET scan.
PATIENTS AND METHODS
Study Design
In October 2006, the European Organisation for Research and Treat-
ment of Cancer (EORTC) Lymphoma Group and the Lymphoma Study
Association (LYSA), formerly GELA (Groupe d’E´tude de Lymphomes Adul-
tes), launched the H10 randomized intergroup trial (EORTC 20051), which
the Intergruppo Italiano Linfomi, now called Fondazione Italiana Linfomi
(FIL), joined in March 2008. The main objective was to evaluate whether
IN-RT could be omitted without loss of efficacy in terms of PFS in patients
with stage I/II HL who attain a negative early PET scan after two cycles of
ABVD (Fig 1). The secondary objective was to evaluate whether intensification
from ABVD to BEACOPP escalated would increase PFS in patients who did
not achieve a negative early PET scan. Eligibility criteria included previously
untreated patients with histologically proven classical HL, supradiaphragmatic
Ann Arbor stage I/II disease, age 15 to 70 years, WHO performance status of 0
to 3, and written informed consent. The number of chemotherapy cycles
depended on the prognostic subgroup: favorable or unfavorable (Fig 1).18,19
The study was approved by the respective scientific boards and national
ethics committees and was registered in ClinicalTrials.gov.20 Patients were
centrally randomly assigned to receive either standard or investigational treat-
ment. A minimization technique was used for treatment allocation in each
prognostic subgroup (favorable v unfavorable), stratifying by institution, Ann
Arbor stage (I v II), and availability of baseline PET.
Early PET Scan
A prospective central reading of the early PET scan was planned in the
protocol.21 For technical reasons, centralized review for the LYSA group
started from the initiation of the trial, and for EORTC/FIL groups, it occurred
from 2008 onward. In case of absence of a timely ( 72 hours) centralized
reading, the local result of the early PET scan was decisional for further
treatment in the experimental arm (first PET interpretation). A blinded sec-
ond central PET review (second central review) was performed retrospectively
after the recommendations of the independent data monitoring commit-
tee (IDMC) by four experts on the scans of 52 patients with events (includ-
ing patients with early PET–negative and early PET–positive scans) and 52
randomly selected patients without events using a dedicated workstation
(POSITOSCOPE; Keosys, Saint-Herblain, France). Twenty of these 104 scans
could not be used for second central review for logistic or technical reasons; 84
were compared with the results of the first review (first central interpretation).
Two experts from LYSA reviewed EORTC/FIL scans and vice versa. PET
images were scored according to the International Harmonisation Project
criteria,22 which were the generally accepted criteria for post-treatment assess-
ment at the start of our trial. According to these criteria, a negative PET
corresponds to scores 1 (no uptake) and 2 (uptake  mediastinum) on the
5-point Deauville scale.23
Statistics
The primary end point was PFS, defined—from the date of random
assignment to date of progression—as relapse after previous complete remis-
sion or progression after reaching partial remission ( 50% decrease and
resolution of B symptoms and no new lesions) or progressive disease (50%
increase from nadir of any previous partial remission lesions or appearance of
new lesions) on computed tomography scan measurements during protocol
treatment or death resulting from any cause, whichever occurred first (censor-
ing rules are given in the Data Supplement).
The primary objective of the study was to evaluate whether the investi-
gational treatment without RT was noninferior to the standard combined-
modality approach in terms of PFS. Each prognostic subgroup (favorable and
unfavorable) was to be analyzed separately, using a log-rank test stratified by
stage (I v II) and availability of baseline PET, with a one-sided significance level
of .025. Assuming a 5-year PFS in the standard arm of 95% for the favorable
subgroup and 90% for the unfavorable subgroup, and allowing for a decrease
of 10% (to 85% and 80%, respectively), the resulting noninferiority margins
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Fig 1. Study design of European Organisation for Research and Treatment of
Cancer, Lymphoma Study Association, and Fondazione Italiana Linfomi H10
20551 trial of patients age 15 to 70 years with untreated supradiaphragmatic
clinical stage I/II Hodgkin lymphoma (excluding nodular lymphocyte–predominant
Hodgkin lymphoma). Favorable (F) status indicates age  50 years with  three
involved nodal areas, absence of mediastinal bulk (mediastinum-to-thorax ratio 
0.35), and erythrocyte sedimentation rate (ESR)  50 mm without B symptoms
or ESR  30 mm with B symptoms. Unfavorable (U) status indicates age  50
years,  four involved nodal areas, presence of mediastinal bulk (mediastinum-
to-thorax ratio  0.35), or ESR  50 mm without B symptoms or ESR  30 mm
with B symptoms. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine;
BEACOPPesc, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincris-
tine, procarbazine, and prednisone escalated; INRT, involved-node radiotherapy;
PET, positron emission tomography; R, random assignment.
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for the hazard ratios (HRs) were 3.2 and 2.1 for favorable and unfavorable
subgroups, respectively. A total of 26 and 63 events (progressions or deaths) for
favorable and unfavorable subgroups, respectively, were required for 80%
power to reject the null hypothesis of inferiority if the true HR were equal to
1.0. Sample size computations allowed for one interim analysis for futility. For
the whole trial, we had planned to recruit 608 and 720 patients, respectively, in
4.5 years. The final analysis was scheduled to be performed after an additional
follow-up of 2 years. No adjustment for multiplicity was made, because the
trial is considered as two independent studies (favorable/unfavorable) embed-
ded in the same protocol.
An interim futility analysis24-26 of the primary end point was scheduled
after documentation of 12 and 22 events (progression, relapse, or death) for
early PET–negative favorable and unfavorable subgroups, respectively. It was
estimated that at that time point, roughly two thirds of the total number of
required patients would be accrued. The purpose of the interim futility
analysis was to stop the recruitment of favorable and unfavorable
patients in case of inferiority of the investigational arm. Because testing
for futility in this noninferiority trial corresponds to testing the hypoth-
esis of no difference between the two arms, a one-sided superiority test
was conducted, with a significance level determined by a Lan-DeMets
spending function (Pocock like) based on the total error of 0.20 (details
are given in the Data Supplement). Stopping boundaries were com-
puted using East software (version 5.3; Cytel, Cambridge, MA). Statis-
tical analysis of the study data was conducted using SAS software
(version 9.1; SAS Institute, Cary, NC). The results of the early PET–
positive group of patients lie outside the scope of this article.
RESULTS
The database was locked for the interim analysis at April 19, 2010. The
analysis was based on patients randomly assigned on or before August
31, 2009, at which time a total of 1,137 patients had been randomly
assigned, with 61%, 25%, and 14% recruited by LYSA, EORTC, and
FIL respectively. Median follow-up at the clinical cutoff date (October
31, 2009) was 1.1 years.
A baseline PET scan was performed in 93.2% of patients. Figure 2
shows the flowchart for patients enrolled in the interim analysis (fa-
vorable subgroup, n 444; unfavorable subgroup, n 693). In the
favorable subgroup, 85.8% (381 of 444) had a negative early PET scan,
and in the unfavorable subgroup, 74.8% (519 of 693) had one. The
frequency of early PET–negative scans was somewhat higher in the
experimental arm (81.2%) than in the standard arm (77.2%). Clinical
characteristics and durations of follow-up were well balanced between
the standard and experimental arms (Table 1). The interim futility
analysis was performed among 1,124 of the 1,137 patients. Eleven
patients did not complete the first two cycles of ABVD or had no early
PET scan performed, and for two patients, no validated data
were available.
Favorable Early PET–Negative Group
In the standard arm, 188 patients were included; in the experi-
mental group, 193 patients (Table 2). A total of 10 events occurred
(standard arm, one event v experimental arm, nine events). All events
were disease progressions (no deaths). On the basis of the actual
information fraction (10 of 26 events required for final analysis) and
the resulting one-sided significance level to perform the statistical test
(.102), futility was declared (P .017 [ie, .102]); that is, on the basis
of this analysis, it was unlikely that we could show equivalent efficacy
between the standard and experimental treatments when continuing
accrual to the originally planned total numbers. The estimated HR was
9.36 (79.6% CI, 2.45 to 35.73). PFS rates at 1 year were 100.0% and
94.9% in the standard and experimental arms, respectively.
Unfavorable Early PET–Negative Group
In the standard arm, 251 patients were included; in the
experimental group, 268 patients (Table 2). A total of 23 events
occurred (standard arm, seven events v experimental arm, 16
(n = 188)
(n = 33) (n = 27) (n = 88) (n = 76)
PET negative
PET positive
(n = 193) (n = 251) (n = 268)
Group C
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Fig 2. Flowchart of patients included
in interim analysis. Group A, favorable
early positron emission tomography (PET)
negative; group B, unfavorable early PET
negative; group C, early PET positive (in-
cluding both favorable and unfavorable).
ABVD, doxorubicin, bleomycin, vinblas-
tine, and dacarbazine.
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events). One patient died as a result of toxicity without signs of
progression; all remaining events were progressions. On the
basis of the actual information fraction (23 of 63 events required
for final analysis) and the resulting one-sided significance level
to perform the statistical test (.098), futility was declared (P 
.026 [ie, .098]). The estimated HR was 2.42 (80.4% CI, 1.35 to
4.36). PFS rates at 1 year were 97.3% and 94.7% in the standard
and experimental arms, respectively.
Conclusion of IDMC and Recommendations
Because the interim futility analysis showed statistical signifi-
cance for PFS in both favorable and unfavorable early PET–negative
groups, the IDMC recommended closing the study for continued
accrual in the early PET–negative experimental arm. Moreover, it
recommended changing treatment in patients with early PET–
negative scans who were randomly assigned to the experimental
arm and had not yet completed treatment from chemotherapy
Table 1. Clinical Characteristics of Patients With Early PET-Negative Disease
Characteristic
Favorable Unfavorable
Total (N  900)
Standard
(n  188)
Experimental
(n  193)
Standard
(n  251)
Experimental
(n  268)
No. % No. % No. % No. % No. %
Age, years
Median 29.5 31 33 31 31
Range 16-49 15-49 16-70 16-70 15-70
Male sex 107 56.9 97 50.3 124 49.4 123 45.9 451 50.1
Ann Arbor clinical stage I 44 23.4 43 22.3 28 11.2 35 13.1 150 16.7
B symptoms 13 6.9 13 6.7 90 35.9 111 41.4 227 25.2
No. of nodal areas
Median 2 2 3 3 2
Range 1-3 1-3 1-5 1-5 1-5
Bulky mediastinum 0 0.0 0 0.0 101 40.2 106 39.5 207 23.0
MT ratio
Median 0.3 0.3 0.3 0.3 0.3
Range 0-0.3 0-0.3 0-0.7 0-0.93 0-0.93
ESR, mm/hr
Overall
Median 14 14 48 40 26
Range 0.8-48 0.3-49 0-143 0-140 0-143
No B symptoms
Median 14 14 18 38 34
Range 0.3-49 1-48 5-29 0-120 0-120
B symptoms
Median 18 20 60 47 45
Range 0.8-29 0-120 10-143 0.3-140 0.3-143
Baseline PET 176 93.6 180 93.3 231 92.0 250 93.3 837 93.0
WHO PS 1-2 16 8.5 9 4.7 43 17.1 58 21.6 126 14.0
Duration of follow–up, years
Median 1.1 1.0 1.1 1.1 1.1
Range 0.1-2.7 0.1-2.9 0.1-2.9 0.1-2.7 0.1-2.9
Abbreviations: ESR, erythrocyte sedimentation rate; MT, mediastinum to thorax; PET, positron emission tomography; PS, performance status..
Table 2. Results of Interim Analysis in Patients With Early PET-Negative Disease
Subset No. of Patients No. of Observed Events HR Adjusted CI P†
1-Year PFS
% Adjusted CI
Favorable .017
Standard 188 1 1.00 100.00
Experimental 193 9 9.36 2.45 to 35.73 94.93 91.89 to 96.85
Unfavorable .026
Standard 251 7 1.00 97.28 95.17 to 98.48
Experimental 268 16 2.42 1.35 to 4.36 94.70 92.11 to 96.46
Abbreviations: HR, hazard ratio; PET, positron emission tomography; PFS, progression-free survival.
Confidence level adjusted to significance level used in interim test: 79.6% CI for favorable group and 80.4% CI for unfavorable group.
†One-sided Wald-test P value of superiority test.
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alone to the standard combined-modality approach, if possible.
The interim analysis of early PET–positive patients did not meet
the criteria for conclusion on the superiority of treatment in-
tensification. Hence, the second question of the trial has not yet
been answered at this interim analysis.
Because not all patients underwent a prospective first central
review, and because of the somewhat higher frequency of early PET
negativity in the experimental arm as compared with the standard
arm, the IDMC recommended performing a blinded second central
review before results of the interim analysis could be reported. This
second central review was performed on early PET scans of all patients
experiencing an event and, as a control group, randomly selected early
PET scans of patients who did not experience an event.
Actions Taken on IDMC Recommendations
The study investigators were informed by letter on the main
conclusion of the interim analysis (ie, stopping accrual in early PET–
negative part of trial). It was advised that all patients who had already
been randomly assigned to the experimental arm but who had not yet
completed treatment or who had completed chemotherapy within the
last 6 weeks be switched to standard-arm treatment (ie, chemotherapy
plus IN-RT). New patients could still be enrolled and randomly as-
signed in the trial, but only for the early PET–positive part of the study.
Therefore, patients with an early PET–negative scan after two cycles of
ABVD would receive the combined-modality treatment, even if they had
beenassignedtotheexperimentalarmatthestartofthetrial.Onlypatients
with an early PET–positive scan remained in their assigned arm.
To ensure sufficient statistical power to address the early PET–
positive objective of the trial, we decided to increase the number of
required patients for the early PET–positive group from 248 to 335
patients.Thisrevisionwasrecommendedbyaseniorstatisticianindepen-
dent from the study team who had access to the actual recruitment rate
and observed event rate in the standard arm. The study was closed to
recruitmentinJune2011,withatotalof1,952randomlyassignedpatients.
Second Central Review of Early PET Scans
Overall, 70% of patients were early PET negative at the first PET
interpretation. At the second central review, six patients included in
the interim analysis of early PET–negative patients would have
changed to early PET positive. Excluding these patients from the
interim analysis, numbers of events in the favorable group changed
from one versus nine to one versus seven; in the unfavorable group,
numbers change from seven versus 16 to five versus 14. The IDMC
concluded that considering these changes, the advantage for the stan-
dard arm persisted.
DISCUSSION
The prescheduled interim futility analysis of the first randomized trial,
to our knowledge, on early PET scan–driven treatment adaptation in
clinical stage I/II HL revealed that more early progressions occurred
after chemotherapy alone than after standard chemotherapy plus
IN-RT in early PET–negative patients. This conclusion held for both
the favorable and unfavorable subsets of patients. Although the num-
bers of events were small, and the median follow-up time was short,
the coordinating study team decided, in line with the conclusions of
the IDMC, to stop enrollment in the early PET–negative part of the
study and to maintain combined-modality treatment as standard for
patients with early PET–negative scans. The results of the blinded
second central review of early PET scans did not change these conclu-
sions. Importantly, the overall early outcome, both in the standard
and experimental arms, was excellent.
The objective of our H10 trial was to determine a robust clinical tool
for selecting patients who could be spared the toxicity of RT without
compromising tumor control. On the basis of the futility interim
analysis, it was unlikely that the study would demonstrate noninferi-
ority for chemotherapy alone in early PET–negative patients. Thus,
omitting IN-RT in early PET–negative patients resulted in a higher
percentage of early relapses than combined-modality treatment.
The interim futility analysis was designed to stop recruitment if
there were significant signals of inferiority of the investigational arm as
compared with the standard arm. Although this was the conclusion,
some questions can be raised. Whether the interim analysis was pre-
mature, in the sense that follow-up time (median, 1.1 years) was short
and the number of events small, can be argued. The noninferiority
margin was based on the assumption that this difference in progres-
sion would outweigh the burden of late toxicity. Admittedly, both
arms had excellent early outcomes, and large proportions of patients
did well with ABVD alone. However, the main goal of our trial was to
find the ideal tool for early detection of patients who do not need RT;
in this setting, early PET scanning did not meet our objective. Another
matter of debate is whether the choice of statistical criteria for declar-
ing futility was sound. However, given the interim data, there was a
low likelihood that the experimental treatment arm would be found to
be noninferior to the standard arm had the trial continued. Given the
accumulated data, and assuming the observed HR trend would be
maintained during the remainder of the trial, the conditional power to
demonstrate noninferiority at the final analysis was 0% in both favor-
able and unfavorable groups. In the rather optimistic scenario where
HR would be equal to 1.0 during the remainder of the trial, the
conditional power to demonstrate noninferiority would be 3% and
30% in favorable and unfavorable subgroups, respectively.
Several randomized studies comparing chemotherapy alone with
combined-modality treatment without using early PET scans have
reached comparable conclusions. The EORTC/GELA H9 study on
patients with favorable clinical stage I/II disease showed a significantly
higher relapse rate in patients receiving chemotherapy alone as com-
pared with those who received 20- or 36-Gy involved-field RT.7 The
Canadian-US Intergroup study, with a somewhat different risk-
adapted design, also revealed higher risk of relapse in patients who did
not undergo irradiation,5 although there were higher toxicity and
death rates in the RT arm. It should be emphasized that subtotal nodal
RT was used in this trial, an RT-strategy that has since been replaced by
the less extensive IF-RT and, more recently, by IN-RT, as used in our
H10 study. In a recent meta-analysis on combined-modality treat-
ment versus chemotherapy alone, the combined approach resulted in
improved tumor control as well as better overall survival.27 A survival
advantage for combined-modality treatment compared with chemo-
therapy alone was demonstrated in a recent large population-
based study.28
A large proportion of patients with favorable clinical stage I/II
disease can be treated with chemotherapy alone, as demonstrated in
this trial. Patients who relapse after chemotherapy alone can often,
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although not always, benefit from intensive salvage treatment. It re-
mains difficult, if not impossible, to balance the advantages of imme-
diate cure with increased toxicity against a higher relapse risk after less
intensive first-line treatment with its consequences for intensive sal-
vage therapy. Thus, the correct treatment strategy is in the eye of the
beholder. The recently completed UK RAPID LH2007 trial29 and the
ongoing German Hodgkin Study Group HD16 and HD17 random-
ized trials, will contribute to the positioning of early PET scanning.
Our interim analysis showed that the risk of early relapse in patients
not undergoing irradiation was significantly higher than that after
combined-modality treatment in early PET–negative patients, even
though both treatment approaches resulted in excellent early out-
come. Final trial analysis will reveal mature outcome data.
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